| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TACR1 |
| Uniprot No | P25103 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-29aa |
| 氨基酸序列 | MDNVLPVDSDLSPNISTNTSEPNQFVQPA |
| 预测分子量 | 30.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TACR1(神经激肽1受体，NK1R)重组蛋白的3篇代表性文献示例(注：文献标题和作者为示例性内容，建议通过学术数据库验证具体信息)：
---
1. **文献名称**：*Structural basis of neurokinin 1 receptor activation and biased signaling*
**作者**：Smith A, et al.
**摘要**：本研究通过重组表达人源TACR1蛋白，解析了其与内源性配体P物质(Substance P)结合的晶体结构，揭示了受体激活的关键构象变化，并探讨了其在G蛋白偏向信号传导中的作用机制。
2. **文献名称**：*Recombinant TACR1 expression in HEK293 cells: A model for studying substance P-mediated inflammatory responses*
**作者**：Chen L, et al.
**摘要**：文章报道了在HEK293细胞中高效表达重组TACR1蛋白的方法，验证了其与Substance P结合的功能活性，并证明该模型可用于筛选靶向NK1R的抗炎化合物。
3. **文献名称**：*TACR1 gene knockout and recombinant protein rescue in a mouse model of chronic pain*
**作者**：Wang Y, et al.
**摘要**：研究利用TACR1基因敲除小鼠模型，通过重组TACR1蛋白回补实验，证实了NK1R在介导慢性疼痛信号中的必要性，为开发镇痛药物提供了分子靶点依据。
---
**提示**：实际文献需通过PubMed、Google Scholar等平台检索关键词“TACR1 recombinant protein”“NK1R expression”或“substance P receptor”获取，重点关注蛋白功能、结构解析或疾病应用方向的研究。
The TACR1 gene encodes tachykinin receptor 1 (TACR1), also known as the neurokinin-1 receptor (NK1R), a G protein-coupled receptor (GPCR) that binds the neuropeptide substance P (SP) with high affinity. As a member of the tachykinin receptor family, TACR1 plays a central role in mediating neurogenic inflammation, pain signaling, and emotional regulation. It is widely expressed in the central and peripheral nervous systems, as well as in immune cells and epithelial tissues. Dysregulation of TACR1 signaling has been implicated in numerous pathological conditions, including chronic pain, depression, anxiety, inflammatory disorders, and cancer progression.
Recombinant TACR1 protein is engineered using heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, functional receptor proteins for structural and functional studies. This recombinant protein retains key domains required for ligand binding and intracellular signaling, enabling researchers to investigate receptor-ligand interactions, downstream signaling pathways (e.g., PLC-IP3. MAPK), and pharmacological modulation. Its production often involves epitope tagging (e.g., His-tag) for simplified purification and detection.
The development of recombinant TACR1 has advanced drug discovery efforts targeting neurokinin pathways. It serves as a critical tool for high-throughput screening of NK1R antagonists, such as aprepitant used in chemotherapy-induced nausea. Structural studies using recombinant protein have also elucidated binding mechanisms of both endogenous peptides and synthetic inhibitors, guiding the design of novel therapeutics for neurological and inflammatory diseases. Current research continues to explore its role in cancer biology and immune modulation, expanding potential clinical applications.
×
